# The Effects of Disulfiram on the Experimental C3H Mouse Embryo 

P. A. C. Thompson and P. I. Folb<br>Department of Clinical Pharmacology, University of Cape Town, Medical School, Anzio Road, Observatory 7925, South Africa


#### Abstract

Key words: disulfiram; teratogenicity. Disulfiram, in 1 mg and 10 mg oral doses, was given to inbred $\mathrm{C}_{3} \mathrm{H}$ mice prior to and for the duration of pregnancy. The effects on the fetus have been assessed at 18 days gestation by means of fetal and placental weights, number of resorptions, skeletal preparations and Wilson's sections. Disulfiram dissolved in diethyl ether was administered to 8 - and 9-day embryos in vitro in concentrations of $0.1,10$ and $100 \mu \mathrm{~g} \mathrm{ml}^{-1}$ of culture medium, and the effects of ether alone and ether plus disulfiram assessed by evaluation of morphological development over a $28-\mathrm{h}$ period, and inhibition of DNA synthesis using tritiated thymidine labelling over a 4-h period. Disulfiram ( 1 mg ) in vivo caused no adverse effects on the fetus, but disulfiram ( 10 mg ) was toxic, in that it caused a significant increase in early resorptions. Disulfiram in vitro, in the 10 and $100 \mu \mathrm{~g} \mathrm{ml}^{-1}$ concentrations, proved to be very toxic to the embryos, affecting both morphological development and DNA synthesis in 9 -day embryos and morphological development in 8 -day embryos. DNA synthesis was only inhibited at the $100 \mu \mathrm{~g} \mathrm{ml}^{-1}$ concentration in 8 -day embryos. The $0.1 \mu \mathrm{~g} \mathrm{ml}^{-1}$ concentration of disulfiram caused abnormal central nervous system development in 8 -day embryos, but was otherwise non-toxic to 8 - and 9 -day embryos. Apart from a reduction in somite counts, ether in concentrations of $0.285 \mathrm{mg} \mathrm{ml}^{-1}$ and $2.85 \mathrm{mg} \mathrm{ml}^{-1}$ caused no adverse effects on morphological development in 8 - or 9 -day embryos. DNA synthesis was inhibited by ether in a concentration of $2.85 \mathrm{mg} \mathrm{ml}^{-1}$ in 9 -day embryos.


## INTRODUCTION

Disulfiram has been linked with teratogenicity in the human fetus ${ }^{1}$ and in experimental Sprague-Dawley rats. ${ }^{2}$ In the former, multiple anomalies, including radial aplasia, vertebral fusion, phocomelia of the lower extremities and tracheo-oesophageal fistula, have been described in association with the drug; in rats, there was an increase in resorption rate in dams treated with disulfiram during pregnancy. It was suggested in the latter that the teratogenicity of the agent may be on the basis of induced copper deficiency due to copper chelating activity.

This study was suggested by our previous conclusions that ethanol and acetaldehyde may be teratogenic in the $\mathrm{C}_{3} \mathrm{H}$ mouse embryos in vivo and in vitro. ${ }^{3}$ The study was designed to detect whether disulfiram teratogenicity could be confirmed in this animal species, and if so whether it is independent of ethanol and its main metabolite acetaldehyde.

## METHODS

## Experimental mice

Inbred female $\mathrm{C}_{3} \mathrm{H}$ mice were mated with $\mathrm{C}_{3} \mathrm{H}$ males at a fixed time. The animals were housed individually in the 1 mg disulfiram in vivo group, and in communal cages in the 10 mg and in vitro groups. Ambient temperature and light-dark intervals were controlled.

## In vivo study

Disulfiram dispergettes containing 400 mg disulfiram as the only active ingredient (supplied by Adcock Ingram Laboratories, Johannesburg) were dissolved in water and administered in a nutritionally balanced liquid feed ${ }^{4}$ in a dose of $1 \mathrm{mg}, 5$ days a week for at least 3 weeks prior to pregnancy and for the duration of gestation. The dose of 1 mg was selected as being approximately $1 / 400$ the lower recommended daily dose of disulfiram in humans. A comparable control group received liquid feed alone. In addition to the liquid feed, the animals had access to rat cubes ${ }^{4}$ (Epol Cape Town) and water ad libitum. They were weighed once weekly for the duration of the experiment.

A 10 mg dose of disulfiram was administered to a second group via an orogastric tube. The control animals received 1 ml of water in place of the disulfiram. It was decided to increase doses on a logarithmic scale; hence, the choice of the 10 mg dose. An attempt was made to administer the disulfiram as described above, but this was not possible, as it tended to sediment out and block the feeding tubes. The animals were sacrificed on day 18 of gestation (day 1 was regarded as the day following mating). Uteri were removed intact and examined for resorptions, and the fetuses were inspected for obvious abnormalities.

Fetuses and placentas were weighed independently, fixed in $10 \%$ saline-buffered formalin, and subsequently divided arbitrarily into two groups for sectioning according to Wilson's method ${ }^{5}$ and detailed skeletal examination by a modification of Dawson's staining method, ${ }^{6}$ respectively. Histological examination was performed on most fetuses,

Table 1. In vivo study - Effects of chronic disulfiram dosage on fetal development ${ }^{\text {a }}$

|  | Wilson's sections (normal) |  | Heart sections |  | Skeietal examination |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Group |  |  | Normal | Abnormal | Normal | Abnormal |
| Disulfiram (1 mg) | Male | 25 | 37 | 1 | 31 | 4 Cervical vertebral bodies invivible: 4 |
|  | Female | 19 |  |  |  |  |
|  | Total | 44 |  |  |  |  |
| Control |  |  |  |  |  | a Invisible or poorly developed supraoccipital bone: lone defect: 0 |
|  | Male | 29 | 59 | 0 | 52 | b Cervical vertebral bodies invisible: 1 |
|  | Female | 33 |  |  |  | c Invisible rib (left 9th rib): 1 |
|  | Total | 62 |  |  |  | d Invisible or poorly developed sternal bones: Ione defect: 0 |
|  |  |  |  |  |  | e Combined defects - $\mathrm{a}, \mathrm{b}$ and d above: 2 |
| Disulfiram (10 mg) | Male | 24 | 30 | 2 | 9 | a Invisible or poorly developed sternal bones: Ione defect: 0 |
|  | Female | 17 |  |  |  | b Invisible or poorly developed supraoccipital bone: lone defect: 0 <br> c Cervical vertebral bodies invisible: 10 |
|  | Total | 41 |  |  |  | c Cervical vertebral bodies invisible: 10 <br> d Combined defect $-a, b$ and $c$ above: 2 |
|  |  |  |  |  |  | e Combined defect - b and c above: 4 |
| Control | Male | 21 | 39 | 2 | 27 | a Invisible or poorly developed supraoccipital bone: lone defect: 0 |
|  | Female | 21 |  |  |  | b Cervical vertebral bodies invisible: 3 |
|  | Total | 42 |  |  |  | c Invisible or poorly developed sternal bones: 1 |
|  |  |  |  |  |  | d Combined defect - b and c above: 1 |
|  |  |  |  |  |  | e Combined defect - $\mathrm{a}, \mathrm{b}$ and c above: 1 |
|  |  |  |  |  |  | f Combined defect - $\mathbf{a}$ and $\mathbf{b}$ above: 6 |

${ }^{\text {a }}$ The 1 mg disulfiram group consisted of 14 dams and 83 live fetuses, and the control group of 18 dams and 118 live fetuses. In the 10 mg disulfiram study, there were 13 dams and 66 live fetuses in the test group, and 12 dams and 81 live fetuses in the control group. Fetuses were assessed at 18 days of gestation. Only live fetuses were included

## Table 2. In vitro study groups ${ }^{\text {a }}$

| Group | Rat serum <br> $(100 \%)$ | Disulfiram <br> $(\mu \mathrm{g} \text { per } \mathrm{ml} \text { serum })^{b}$ | Diethyl ether <br> $(\mathrm{mg} \text { per } \mathrm{ml} \text { serum })^{c}$ |
| :--- | :--- | :--- | :--- |
| 1 | + | - | - |
| 2 | + | - | 2.85 |
| 3 | + | - | 0.285 |
| 4 | + | 0.1 | 0.285 |
| 5 | + | 10.0 | 0.285 |
| 6 | + | 100.0 | 2.85 |

${ }^{a}$ The $0.285 \mathrm{mg} \mathrm{ml}^{-1}$ ether group served as control for the 0.1 $\mu \mathrm{g} \mathrm{ml}^{-1}$ and $10 \mu \mathrm{~g} \mathrm{ml}^{-1}$ disulfiram groups, and the $2.85 \mathrm{mg} \mathrm{ml}^{-1}$ ether groups as control for the $100 \mu \mathrm{~g} \mathrm{ml}^{-1}$ disulfiram group. The embryos cultured in pure rat serum served as controls for the $b$ embryos cultured in ether.
${ }^{b}$ Disulfiram, pure substance supplied by MPS Laboratories, Johannesburg.
c Diethyl ether, analytical grade, Merck Darmstadt.
which on sectioning appeared abnormal. Fetal hearts were examined in those fetuses used for Wilson's sectioning by a method of microdissection, ${ }^{4}$ which enabled detailed examination to be carried out of the atria, atrial appendages, ventricles, aortic and pulmonary valves, coronary arteries and major vessels. The numbers of animals in the test and control groups are indicated in Table 1.

Fetuses were regarded as normal if no abnormalities were detected at 18 days by the criteria referred to above. The skeleton was not considered abnormal at 18 days if the digits were not visible, provided all other bones were clearly identified.

## In vitro study

An in vitro mouse embryo culture system, based on the method described by New, ${ }^{7}$ was used in this investigation. The method was as we have described previously, ${ }^{3}$ except that sterile heat-inactivated rat serum was used as the culture medium and plastic tubes were used instead of glass. Eight and 9-day embryos were divided into six groups as indicated in Table 2. There were 10 eight-day embryos and 22 nine-day embryos in group 1. The number of embryos in the remaining groups is indicated in Tables 3 and 4.

## DNA synthesis

This was examined in the manner we have reported previously. ${ }^{3}$

## Morphological assessment

This was carried out for 8 - and 9 -day embryos in the manner which we have reported previously. ${ }^{3}$

## RESULTS

The detailed results of in vivo administration of 1 and 10 mg disulfiram, respectively, are given in Table 1. In the lower dose, there was no significant reduction in fetal or placental weights, or increase in resorption rate, intrauterine deaths, frequency of external or skeletal abnormalities, or alteration in sex ratio compared with controls.
Table 3. In vitro study - Effects of disulfiram on 8-day mouse embryos ${ }^{\text {a }}$

| Dose of disulfiram ( $\mu \mathrm{g} \mathrm{ml}^{-1}$ ) | Heart - Present - Absent | Heart beat Present - Absent | Somite count | Neural tube defects | CNS development | DNA synthesis ${ }^{\text {b }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0.1 | No significant effect on development <br> Control: $n=16$ <br> Test: $n=16$ | No significant effect on heart beat <br> Control: $n=16$ <br> Test: $n=16$ | No significant effect (Mann-Whitney Test) Control: $n=15$ Test: $\boldsymbol{n}=\mathbf{1 5}$ | No significant increase in neural tube defects <br> Control: $n=16$ <br> Test: $n=16$ | CNS development significantly abnormal ( $p=0.042$ ) <br> Control: $n=16$ <br> Test: $n=16$ | No significant reduction in DNA synthesis in test group (Mann-Whitney Test) <br> Control: $n=15$ <br> Test: $n=15$ |
| 10 | Significant adverse effect on heart development in test group ( $p<0.001$ ) <br> Control: $n=16$ <br> Test: $n=17$ | Significant adverse effect on heart beat in test group $(p<0.001)$ <br> Control: $n=16$ <br> Test: $n=17$ | Somite count significantly reduced in test group ${ }^{\text {c }}$ $(p<0.001)$ <br> (Mann-Whitney Test) <br> Contral: $n=16$ <br> Test: $n=17$ | Significant increase in neural tube defects in test group ( $p<0.001$ ) <br> Control: $n=16$ <br> Test: $n=17$ | CNS development signifi- <br> ficantly abnormal $(p<0.001)$ <br> Control: $n=16$ <br> Test: $n=17$ | No significant reduction in DNA synthesis in test group (Mann-Whitney Test) <br> Control: $n=15$ <br> Test: $n=16$ |
| 100 | Significant adverse effect on heart development in test group ( $p<0.001$ ) <br> Control: $n=20$ <br> Test: $n=17$ | Significant adverse effect on heart beat in test group ( $p<0.001$ ) <br> Control: $n=\mathbf{2 0}$ <br> Test: $n=17$ | Somite count significantly reduced in test group ${ }^{c}$ $(p<0.001)$ <br> (Mann-Whitney Test) <br> Controi: $n=20$ <br> Test: $n=17$ | Significant increse in neural tube defects in test group ( $p<0.001$ ) <br> Control: $n=20$ <br> Test: $n=17$ | CNS development significantly abnormal ( $p<0.001$ ) <br> Control: $n=20$ <br> Test: $n=17$ | Significant reduction of DNA synthesis in test group ( $\rho<0.05$ ) (Mann-Whitney Test) Control: $n=19$ Test: $n=15$ |
| ${ }^{\mathrm{a}}$ The Fisher Exact <br> ${ }_{c}$ Detailed resuits 9 <br> ${ }^{c}$ No somites were | ability Test was used, excep Table 5. <br> in any of the test embryo | ere otherwise indicated. <br> he 10 and $100 \mu \mathrm{~g} \mathrm{~m}^{-1}$ dis | firam groups. |  |  |  |

Table 4. In vitro study - Effects of disulfiram on 9-day mouse embryos ${ }^{\text {a }}$

| Dose of disulfiram ( $\mu \mathrm{g} \mathrm{m} \mathrm{m}^{-1}$ ) | Somite count | Heart beatPresent - Absent | Development of visceral arches | CNS development | DNA synthesis ${ }^{\text {b }}$ | Neural tube defects |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0.1 | No significant effect (Mann-Whitney Test) Control: $n=25$ <br> Test: $n=\mathbf{2 6}$ | No significant effect on heart beat <br> Control: $n=26$ <br> Test: $n=\mathbf{2 5}$ | No significant abnormality <br> Control: $n=26$ <br> Test: $n=\mathbf{2 5}$ | CNS development normal <br> Control: $n=26$ <br> Test: $n=\mathbf{2 5}$ | No significant reduction in DNA synthesis in test group (Mann-Whitney Test) <br> Control: $n=25$ <br> Test: $\boldsymbol{n}=\mathbf{2 4}$ | No significant increase in neural tube defects <br> Control: $n=26$ <br> Test: $n=\mathbf{2 5}$ |
| 10 | Somite count significantly reduced in test group ${ }^{\text {c }}$ $(\rho<0.001)$ <br> (Mann-Whitney Test) <br> Control: $n=26$ <br> Test: $n=21$ | Significant adverse effect on heart beat in test group ( $p=0.05$ ) <br> Control: $n=26$ <br> Test: $n=24$ | Significant abnormality in test group ( $\rho=0.009$ ) <br> Control: $n=26$ <br> Test: $n=24$ | CNS development significantly abnormal in test group ( $p<0.001$ ) <br> Control: $n=26$ <br> Test: $n=24$ | Significant reduction in DNA synthesis in test group ( $p<0.001$ ) <br> (Mann-Whitney Test) <br> Control: $n=25$ <br> Test: $\boldsymbol{n}=\mathbf{2 1}$ | Significant increase in neural tube defects in test group $(\rho<0.001)$ <br> Control: $n=26$ <br> Test: $n=\mathbf{2 4}$ |
| 100 | Somite count significantly reduced in test group ${ }^{\text {c }}$ $(p<0.001)$ <br> (Mann-Whitney Test) <br> Control: $n=24$ <br> Test: $n=5$ | Significant adverse effect on heart beat in test group ( $\rho<0.001$ ) <br> Control: $n=24$ <br> Test: $n=\mathbf{2 5}$ | Significant abnormality in the test group ( $p<0.001$ ) <br> Control: $n=24$ <br> Test: $n=\mathbf{2 5}$ | CNS development significantly abnormal in test group $(\rho<0.001)$ <br> Control: $n=24$ <br> Test: $n=25$ | Significant reduction in DNA synthesis in test group ( $p=0.001$ ) (Mann-Whitney Test) Control: $n=24$ Test: $n=\mathbf{2 0}$ | Significant increase in neural tube defects in test group ( $p<0.001$ ) <br> Control: $n=24$ <br> Test: $n=\mathbf{2 5}$ |

a The Fisher Exact Probability Test was used, except where otherwise indicated. The development of limb buds, optic and otic vesicles, and the degree of turning of the embryos was very significantly affected ( $p<0.001$ ) in the two higher disulfiram dose groups studied. Heart development was not affected in any of the groups.
c Only embryos in which it was possible to count somites were included. The remainder were too deformed to assess.

Table 5. In vitro model - Tritiated thymidine uptake of embryos explanted at 8-days gestation ${ }^{\text {a }}$

| Rat serum 100\% (dpm) | Diethyl ether $2.85 \mathrm{mg} \mathrm{ml}^{-1}$ (dpm) | Diethyl ether $0.285 \mathrm{mg} \mathrm{ml}^{-1}$ (dpm) | $0.1 \mu \mathrm{~g} \mathrm{ml}^{-1}$ <br> disulfiram <br> in diethyl ether (dpm) | $10.0 \mu \mathrm{~g} \mathrm{ml}^{-1}$ disulfiram in diethyl ether (dpm) | $100.0 \mu \mathrm{~g} \mathrm{ml}^{-1}$ <br> disulfiram in diethyl ether (dpm) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 308.0 | 0 | 0 | 980.5 | 0 | 157.3 |
|  | 0 | 0 | 566.8 | 0 | 0.5 |
| 679.4 | 0 | 0.5 | 38.1 | 73.8 | 0 |
| 892.2 | 0 | 529.0 | 365.8 | 0.6 | 297.7 |
| 0 | 0.5 | 0.5 | 432.5 | 0 | 36.8 |
| 469.9 | 0 | 629.9 | 321.0 | 0 | 128.3 |
| 0 | 465.7 | 247.6 | 673.6 | 0 | 69.0 |
| 503.0 | 318.2 | 0 | 487.5 | 0 | 126.6 |
| 37.2 | 314.4 | 1671.7 | 200.1 | 0 | 0.5 |
| 0 | 0.5 | 65.3 | 752.6 | 0 | 149.6 |
|  | 209.9 | 757.2 | 0.5 | 0.5 | 289.3 |
|  | 0 | 1485.3 | 1202.5 | 0 | 211.2 |
|  | 344.6 | 1045.4 | 639.2 | 644.7 | 215.5 |
|  | 342.6 | 0 | 1272.2 | 0 | 172.6 |
|  | 1269.2 | 1117.3 | 2453.7 | 0.5 | 293.4 |
|  | 146.5 |  |  |  | 273.4 |
|  | 1685.8 |  |  |  |  |
|  | 1627.7 |  |  |  |  |
|  | 773.7 |  |  |  |  |

Table 6. In vitro model - Tritiated thymidine uptake of embryos explanted at 9-days gestation ${ }^{\text {a }}$

| Rat serum 100\% (dpm) | Diethyl ether $2.85 \mathrm{mg} \mathrm{ml}^{-1}$ (dpm) | Diethyl ether $0.285 \mathrm{mg} \mathrm{m}^{-1}$ (dpm) | $0.1 \mu \mathrm{~g} \mathrm{~m}^{-1}$ disulfiram in diethyl ether (dpm) | $10 \mu \mathrm{~g} \mathrm{ml}^{-1}$ <br> disulfiram in diethyl ether (dpm) | $\begin{aligned} & 100 \mu \mathrm{~g} \mathrm{ml}^{-1} \\ & \text { disulfiram } \\ & \text { in diethyl ether } \\ & \text { (dpm) } \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 15048.6 | 0 | 16368.7 | 12094.7 | 372.8 | 0.5 |
| 12656.3 | 80.2 | 14452.7 | 25572.5 | 1134.0 | 0 |
| 13785.6 | 0 | 0.6 | 4446.4 | 0.6 | 105.1 |
| 28846.2 | 0 | 1209.2 | 24298.4 | 363.2 | 70.2 |
| 30836.4 | 883.2 | 6365.9 | 14529.0 | 1019.0 | 0.5 |
| 18267.1 | 1696.1 | 7019.1 | 14529.0 | 797.0 | 57.6 |
| 30643.4 | 569.4 | 8874.3 | 2150.7 | 0 | 0 |
| 12912.8 | 758.1 | 12357.3 | 9943.5 | 695.6 | 72.1 |
| 5768.3 | 918.8 | 4100.4 | 15936.3 | 529.7 | 0.5 |
| 19449.2 | 1873.2 | 967.8 | 5388.2 | 509.3 | 227.8 |
| 10039.1 | 0 | 13601.7 | 5539.6 | 1016.6 | 0.6 |
| 5281.0 | 9907.4 | 7987.6 | 12627.5 | 0 | 154.1 |
| 5305.2 | 7731.2 | 233714 | 17147.0 | 41.9 | 131.8 |
| 15128.1 | 16287.8 | 26347.8 | 21608.8 | 3978.1 | 102.6 |
| 8412.1 | 5849.5 | 16245.1 | 19556.9 | 3169.6 | 176.1 |
| 22830.0 | 7528.2 | 17266.6 | 7186.5 | 2940.7 | 0 |
| 21182.5 | 4143.8 | 16340.1 | 8676.8 | 916.4 | 0 |
| 10916.8 | 7368.9 | 9286.6 | 0 | 1711.1 | 0 |
| 7261.1 | 8803.8 | 153.1 | 0.5 | 776.9 | 0 |
| 4738.2 | 21402.2 | 21035.2 | 10389.2 | 2424.9 |  |
| 4628.9 | 6326.8 | 8284.6 | 8806.0 | 405.7 |  |
|  | 9334.4 | 30723.5 | 7465.4 |  |  |
|  | 4233.1 | 4553.2 | 6762.5 |  |  |
|  |  | 6525.6 | 12341.2 |  |  |
|  |  | 1452.7 |  |  |  |

Table 7. Maternal and fetal details relating to $\mathrm{C}_{3} \mathrm{H}$ mice treated with 1 mg disulfiram daily, and their controls ${ }^{\mathrm{a}}$

| Fetal parameters (test group) |  |  |  |  |  | Fetal parameters (control group) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Litter number | Number of fetuses | Range of fetal weights (g) | External abnormality or death | Early resorptions | Range of placental weights (g) | Litter number | Number of fetuses | Range of fetal weights (g) | External abnormality or death | Early resorptions | Range of placental weights (g) |
| 1 | 7 | 0.8932-1.01185 <br> Mean <br> $1.0241 \pm 0.0795$ | - | 1 | 0.1188-0.1565 <br> Mean <br> $0.1409 \pm 0.0155$ | 1 | 10 | 0.9583-1.1436 <br> Mean <br> $1.0336 \pm 0.0554$ | One monster or late resorption | 0 | 0.0885-0.1531 <br> Mean <br> $0.1085 \pm 0.0182$ |
| 2 | 7 | $\begin{aligned} & 0.6570-1.1012 \\ & \text { Mean } \\ & 0.9052 \pm 0.1486 \end{aligned}$ | - | 0 | $\begin{aligned} & 0.1074-0.1803 \\ & \text { Mean } \\ & 0.1469 \pm 0.0282 \end{aligned}$ | 2 | 7 | $\begin{aligned} & 0.6085-1.2235 \\ & \text { Mean } \\ & 1.0929 \pm 0.2182 \end{aligned}$ | - | 1 | $\begin{aligned} & 0.1077-0.1703 \\ & \text { Mean } \\ & 0.1385 \pm 0.0213 \end{aligned}$ |
| 3 | 8 | $\begin{aligned} & 0.9045-1.0672 \\ & \text { Mean } \\ & 0.9696 \pm 0.0495 \end{aligned}$ | - | 2 | $\begin{aligned} & 0.1433-0.2342 \\ & \text { Mean } \\ & 0.1719 \pm 0.0278 \end{aligned}$ | 3 | 6 | $\begin{aligned} & 0.9505-1.1905 \\ & \text { Mean } \\ & 1.1030 \pm 0.0906 \end{aligned}$ | One monster or late resorption | 2 | $0.1111-0.1801$ <br> Mean $0.1442 \pm 0.0247$ |
| 4 | 10 | $\begin{aligned} & 0.8697-1.0375 \\ & \text { Mean } \\ & 0.9756 \pm 0.0525 \end{aligned}$ | - | 0 | $\begin{aligned} & 0.1283-0.2245 \\ & \text { Mean (twins) } \\ & 0.1546 \pm 0.0295 \end{aligned}$ | 4 | 5 | $\begin{aligned} & 1.1242-1.1755 \\ & \text { Mean } \\ & 1.1508 \pm 0.0236 \end{aligned}$ | - | 0 | $\begin{aligned} & 0.1230-0.1700 \\ & \text { Mean } \\ & 0.1332 \pm 0.0206 \end{aligned}$ |
| 5 | 7 | $\begin{aligned} & 0.8292-1.0246 \\ & \text { Mean } \\ & 0.9454 \pm 0.0627 \end{aligned}$ | - | 2 | $\begin{aligned} & 0.1095-0.1972 \\ & \text { Mean } \\ & 0.1416 \pm 0.0272 \end{aligned}$ | 5 | 10 | $\begin{aligned} & 0.8813-1.0727 \\ & \text { Mean } \\ & 0.9711 \pm 0.0666 \end{aligned}$ | - | 1 | $\begin{aligned} & 0.0900-0.1400 \\ & \text { Mean } \\ & 0.1073 \pm 0.0134 \end{aligned}$ |
| 6 | 6 | $\begin{aligned} & 0.8051-1.2123 \\ & \text { Mean } \\ & 1.0168 \pm 0.1391 \end{aligned}$ | - | 0 | $\begin{aligned} & 0.1112-0.1649 \\ & \text { Mean } \\ & 0.1413 \pm 0.0201 \end{aligned}$ | 6 | 9 | $\begin{aligned} & 0.7956-1.0654 \\ & \text { Mean } \\ & 0.9459 \pm 0.0763 \end{aligned}$ | - | 0 | $\begin{aligned} & 0.0765-0.1320 \\ & \text { Mean } \\ & 0.1130 \pm 0.0174 \end{aligned}$ |
| 7 | 8 | $\begin{aligned} & 0.9350-1.1162 \\ & \text { Mean } \\ & 1.0512 \pm 0.0682 \end{aligned}$ | One monster or late resorption | 0 | $\begin{aligned} & 0.1158-0.1383 \\ & \text { Mean } \\ & 0.1269 \pm 0.0091 \end{aligned}$ | 7 | 9 | $\begin{aligned} & 0.7895-0.9800 \\ & \text { Mean } \\ & 0.8824 \pm 0.0777 \end{aligned}$ | - | 0 | $\begin{aligned} & 0.0915-0.1517 \\ & \text { Mean } \\ & 0.1127 \pm 0.0184 \end{aligned}$ |
| 8 | 7 | $\begin{aligned} & 0.9796-1.1500 \\ & \text { Mean } \\ & 1.0546 \pm 0.0587 \end{aligned}$ | One monster or late resorption | 1 | $\begin{aligned} & 0.1199-0.1826 \\ & \text { Mean } \\ & 0.1581 \pm 0.0256 \end{aligned}$ | 8 | 8 | $\begin{aligned} & 0.6039-1.1662 \\ & \text { Mean } \\ & 0.9974 \pm 0.1829 \end{aligned}$ | One monster or late resorption | 0 | $\begin{aligned} & 0.0820-0.1263 \\ & \text { Mean } \\ & 0.1070 \pm 0.0143 \end{aligned}$ |
| 9 | 7 | 0.6469-1.0972 <br> Mean <br> $0.9712 \pm 0.1641$ | Abnormal hind limb | 2 | 0.0678-0.1123 Mean <br> $0.0962 \pm 0.0166$ | 9 | 10 | 0.8562-1.0434 <br> Mean <br> $0.9565 \pm 0.0641$ | - | 0 | $\begin{aligned} & 0.0781-0.1111 \\ & \text { Mean } \\ & 0.0978 \pm 0.0115 \end{aligned}$ |


| 10 | 6 | $\begin{aligned} & 0.6930-1.1684 \\ & \text { Mean } \\ & 0.9557 \pm 0.1818 \end{aligned}$ | - | 1 | $\begin{aligned} & 0.0893-0.2234 \\ & \text { Mean (twins) } \\ & 0.1319 \pm 0.0533 \end{aligned}$ | 10 | 8 | $\begin{aligned} & 0.9802-1.2123 \\ & \text { Mean } \\ & 1.0860 \pm 0.0781 \end{aligned}$ | One monster or late resorption and one dead fetus | 1 | $0.1013-0.3167$ <br> Mean (twins) $0.1776 \pm 0.0755$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 11 | 8 | 0.8400-1.1300 Mean <br> $1.0533 \pm 0.0907$ | - | 0 | 0.0900-0.1338 <br> Mean <br> $0.1086 \pm 0.0128$ | 11 | 9 | 0.7320-1.1124 Mean $0.9666 \pm 0.1258$ | One monster or late resorption | 1 | 0.1022-0.2121 Mean (twins) $0.1479 \pm 0.0378$ |
| 12 | 9 | $\begin{aligned} & 0.9334-1.1494 \\ & \text { Mean } \\ & 1.0364 \pm 0.0707 \end{aligned}$ | One monster or late resorption | 1 | $\begin{aligned} & 0.0887-0.1225 \\ & \text { Mean } \\ & 0.1066 \pm 0.0124 \end{aligned}$ | 12 | 10 | $\begin{aligned} & 0.8760-1.1309 \\ & \text { Mean } \\ & 1.0083 \pm 0.5760 \end{aligned}$ | One dead fetus | 0 | $0.1144-0.1596$ <br> Mean $0.1377 \pm 0.0165$ |
| 13 | 9 | $\begin{aligned} & 0.9141-1.2004 \\ & \text { Mean } \\ & 1.0673 \pm 0.0827 \end{aligned}$ | One monster or late resorption and one dead fetus with exomphalos | 0 | $\begin{aligned} & 0.0942-0.2298 \\ & \text { Mean } \\ & 0.1202 \pm 0.0487 \end{aligned}$ | 13 | 6 | $\begin{aligned} & 0.7014-1.1600 \\ & \text { Mean } \\ & 0.9778 \pm 0.1637 \end{aligned}$ | - | 2 | $\begin{aligned} & 0.1019-0.2062 \\ & \text { Mean } \\ & 0.1566 \pm 0.0360 \end{aligned}$ |
| 14 | 10 | $\begin{aligned} & 0.8828-1.0624 \\ & \text { Mean } \\ & 0.9842 \pm 0.0623 \end{aligned}$ | One dead fetus | 0 | $\begin{aligned} & 0.0897-0.1282 \\ & \text { Mean } \\ & 0.1050 \pm 0.0114 \end{aligned}$ | 14 | 8 | $\begin{aligned} & 0.9990-1.1614 \\ & \text { Mean } \\ & 1.0772 \pm 0.0758 \end{aligned}$ | One monster or late resorption and one dead fetus | 2 | $\begin{aligned} & 0.0961-0.1693 \\ & \text { Mean } \\ & 0.1412 \pm 0.0313 \end{aligned}$ |
|  |  |  |  |  |  | 15 | 8 | 0.7293-1.0359 Mean $0.9311 \pm 0.0935$ | One fetus with exomphalos | 0 | 0.1257-0.3135 <br> Mean (twins) <br> $0.1795 \pm 0.0630$ |
|  |  |  |  |  |  | 16 | 7 | $\begin{aligned} & 0.8300-1.1269 \\ & \text { Mean } \\ & 1.0025 \pm 0.0926 \end{aligned}$ | - | 0 | $\begin{aligned} & 0.0832-0.1130 \\ & \text { Mean } \\ & 0.1056 \pm 0.0101 \end{aligned}$ |
|  |  |  |  |  |  | 17 | 8 | $\begin{aligned} & 0.9090-1.0343 \\ & \text { Mean } \\ & 0.9696 \pm 0.0502 \end{aligned}$ | - | 3 | $\begin{aligned} & 0.0851-0.1061 \\ & \text { Mean } \\ & 0.0946 \pm 0.0079 \end{aligned}$ |
|  |  |  |  |  |  | 18 | 9 | $\begin{aligned} & 0.9440-1.0895 \\ & \text { Mean } \\ & 1.0292 \pm 0.0499 \end{aligned}$ | One monster or late resorption | 1 | $\begin{aligned} & 0.1000-0.1800 \\ & \text { Mean } \\ & 0.1329 \pm 0.0263 \end{aligned}$ |


| Fetal parameters (test group) |  |  |  |  |  | Fetal parameters (control group) |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Litter number | Number <br> of <br> fetuses | Range of fetal weights (g) | External abnormality or death | Early resorptions | Range of placental weights (g) | Litter number | Number <br> of <br> fetuses | Range of fetal weights (g) | External abnormality or death | Early resorptions | Range of placental weights (g) |
| 1 | 5 | $\begin{aligned} & 1.2810-1.3525 \\ & \text { Mean } \\ & 1.3230 \pm 0.0307 \end{aligned}$ | - | 3 | 0.0845-0.1114 <br> Mean <br> $0.0991 \pm 0.0133$ | 1 | 8 | 0.5189-0.7480 <br> Mean <br> $0.6439 \pm 0.0755$ | - | 0 | 0.1010-0.1355 Mean <br> $0.1179 \pm 0.0133$ |
| 2 | 8 | 0.6070-0.8066 Mean <br> $0.7139 \pm 0.0627$ | - | 0 | 0.1013-0.1574 Mean $0.1237 \pm 0.0216$ | 2 | 9 | 0.5132-0.8136 Mean $0.6869 \pm 0.1177$ | - | 1 | 0.0968-0.1357 <br> Mean <br> $0.1148 \pm 0.0153$ |
| 3 | 9 | 0.7905-1.0246 Mean $0.9176 \pm 0.0750$ | - | 0 | 0.0695-0.1095 Mean $0.0949 \pm 0.0120$ | 3 | 6 | 0.9944-1.0326 <br> Mean <br> $1.0479 \pm 0.0451$ | - | 1 | 0.0900-0.1538 Mean <br> $0.1164 \pm 0.0221$ |
| 4 | 6 | $\begin{aligned} & 0.7334-0.9508 \\ & \text { Mean } \\ & 0.8580 \pm 0.0979 \end{aligned}$ | Monster or late resorption | 0 | 0.0952-0.1519 <br> Mean <br> $0.1137 \pm 0.0223$ | 4 | 6 | 0.7027-1.0647 <br> Mean <br> $0.9457 \pm 0.1285$ | - | 0 | $\begin{aligned} & 0.0943-0.1630 \\ & \text { Mean } \\ & 0.1369 \pm 0.0279 \end{aligned}$ |
| 5 | 7 | 0.8101-1.1578 Mean <br> $0.9803 \pm 0.1176$ | - | 0 | 0.1410-0.1791 <br> Mean <br> $0.1560 \pm 0.0158$ | 5 | 7 | 0.9414-1.1119 Mean <br> $0.9833 \pm 0.0770$ | One dead fetus | 0 | $\begin{aligned} & 0.1200-0.1439 \\ & \text { Mean } \\ & 0.1296 \pm 0.0083 \end{aligned}$ |
| 6 | 5 | 0.9048-1.0186 Mean $0.9387 \pm 0.0536$ | Monster or late resorption | 2 | 0.1315-0.2300 Mean <br> $0.1688 \pm 0.0432$ | 6 | 7 | $\begin{aligned} & 0.9353-1.0610 \\ & \text { Mean } \\ & 0.9933 \pm 0.0447 \end{aligned}$ | - | 0 | 0.1118-0.1741 Mean <br> $0.1360 \pm 0.0201$ |



In the 10 mg dose, disulfiram exerted no detectable effect on any of these parameters, besides the resorption rate, which was significantly increased. Late resorptions or monsters were included in intra-uterine deaths.

The results of the in vitro studies of 8 - and 9 -day embryos are given in Tables 3 and 4, respectively. The data concerning group 1 which served as an internal control for groups 2 and 3 has not been included in the tables, as they did not differ materially. The detailed results of tritiated thymidine uptake in the various groups are given in Tables 5 and 6.

Disulfiram in low dosage caused central nervous system abnormalities in 8-day embryos, but no other abnormalities were detected in either 8 - or 9 -day embryos at this dosage. Concentrations of 10 and $100 \mu \mathrm{~g} \mathrm{ml}^{-1}$ disulfiram proved to be highly toxic to both 8 - and 9 -day embryos, affecting most of the criteria which were examined.

DNA synthesis was significantly reduced by the highest dose of disulfiram in 8 -day embryos. In the 9 -day-old embryos, DNA synthesis was inhibited in the 10 and 100 $\mu \mathrm{g} \mathrm{ml}^{-1}$ disulfiram groups.

In the concentrations studied, diethyl ether caused no detectable morphological abnormalities in 8- or 9-day embryos besides a reduction in the somite counts in 8 - and 9 -day embryos in the higher concentration ( $p=0.05$ and 0.003 , respectively).

Neither concentration of diethyl ether had an effect on DNA synthesis of 8 -day embryos. DNA synthesis was inhibited by 2.85 mg of diethyl ether per ml in 9 -day embryos ( $p=0.0002$ ). This finding was associated with a reduction in somite count, but not with other detectable morphological abnormalities.

Two fetuses in the 10 mg disulfiram control group had abnormal hearts. In one there was a dilated right ventricle, and in the other a small heart was noted, with the aorta and pulmonary artery abnormally approximated. The origin of the pulmonary artery in this heart was anterior to its normal position.

In the group treated with 10 mg disulfiram, one fetus had a small aorta and dilated pulmonary artery, and the
other had a small heart associated with what appeared to be a truncus arteriosus.

Further details regarding the condition of the dams in their pre-pregnant and pregnant state, and fetal weight, frequency of abnormalities, deaths or resorptions and placental weight of test and control animals are provided in Tables 7 and 8.

## DISCUSSION

The high dose of disulfiram ( 10 mg daily) was associated with a significant increase in resorptions, but not with any other identifiable morphological abnormalities in those fetuses which survived. Possible disulfiram-induced biochemical or functional abnormalities were not examined in this study, and cannot be excluded.

The in vitro findings suggest a teratogenic effect of disulfiram in high doses. The findings of a reduction of DNA synthesis in 8 - and 9 -day embryos with the higher doses of disulfiram were not consistently related to morphological evidence of abnormal central nervous system development. Our previous experience (with larger numbers) gave good correlation between inhibition of DNA synthesis and abnormal central nervous system development caused by two mouse teratogens, ethanol and acetaldehyde.

Our conclusion is that disulfiram, given in high pharmacological doses to $\mathrm{C}_{3} \mathrm{H}$ mice prior to and during pregnancy, exerts a teratogenic effect. There was an indication that this toxic effect of disulfiram is dose-related.

## Acknowledgement

This work was supported by grants from the South African Medical Research Council and the University of Cape Town Staff Research Fund.

## REFERENCES

1. A. H. Nora, J. J. Nora and J. Blu, Limb reduction anomalies in infants born to disulfiram-treated alcoholic mothers. Lancet ii (8039), 664 (1977).
2. M. P. Salgo and G. Oster, Fetal resorption induced by disulfiram in rats. J. Reproduction and Fertility 39, 375-377 (1974).
3. P. A. C. Thompson and P. I. Folb, An in vitro model of alcohol and acetaldehyde teratogenicity. J. Appl. Toxicol. 2, 190-195 (1982).
4. P. A. C. Thompson, A study of the pathogenesis of fetal damage caused by ethanol in the experimental mouse. Doctoral Thesis,

University of Cape Town (1982)
5. M. V. Barrow and W. J. Taylor, A rapid method for detecting malformations in rat fetuses. J. Morphol. 127, 291-306 (1969).
6. G. W. Richmond and L. Bennett, Modified Dawson's method for staining fetal skeletons. Stain Technol. 13, 77 (1938).
7. D. A. T. New, Whole embryo culture and the study of mammalian embryos during organogenesis. Biol. Rev. 53, 81122 (1978).

Received 7 March 1983; accepted (revised) 17 November 1983

